Antiplatelet and Antithrombotic Therapy in Type I Diabetes Mellitus: Update on Current Data.

Abstract

Diabetes mellitus type 1 (T1DM) is an autoimmune disease characterized by a markedly elevated cardiovascular (CV) risk due to premature atherosclerosis. Previous studies have shown that intense glycemic control reduces the incidence of CV disease. Antiplatelet therapy is considered to be a very important therapy for secondary prevention of recurrent atherothrombotic events in patients with DM, while it may be considered for primary prevention in individuals with T1DM with additional CV risk factors. The aim of the present review is to summarize existing literature data regarding the thrombotic risk in T1DM patients and discuss current treatment strategies.

• Authors: Spyridon Maragkoudakis, Vasiliki Katsi, Andreas Melidonis, Stergios Soulaidopoulos, Genovefa D Kolovou, Athanasia K Papazafeiropoulou, Aikaterini Trikkalinou, Konstantinos Toutouzas, Konstantinos Tsioufis
• Journal: Current diabetes reviews (Curr Diabetes Rev) Vol. 18 Issue 9 Pg. e030122199792 ( 2022) ISSN: 1875-6417 [Electronic] United Arab Emirates
• PMID: 34979890 (Publication Type: Journal Article, Review)
• Copyright: Copyright© Bentham Science Publishers; For any queries, please email at [email protected].

Chemical References

• Fibrinolytic Agents
• Platelet Aggregation Inhibitors

Topics

• Atherosclerosis (drug therapy, prevention & control)
• Cardiovascular Diseases (epidemiology, etiology, prevention & control)
• Diabetes Mellitus, Type 1 (complications, drug therapy)
• Fibrinolytic Agents (therapeutic use)
• Humans
• Platelet Aggregation Inhibitors (therapeutic use)
• Secondary Prevention